Literature DB >> 2726105

Resection of the pubic bone as an adjunct to management of primary, recurrent, and metastatic pelvic malignancies.

L A King1, G O Downey, J E Savage, L B Twiggs, G J Oakley, K A Prem.   

Abstract

Patients with locally advanced vulvovaginal carcinomas with pubic bone encroachment or fixation pose a treatment dilemma. The purpose of this study was to evaluate the outcome in 12 patients who have undergone pubic bone resection at the University of Minnesota as part of treatment of locally extensive primary, recurrent, or metastatic vulvovaginal carcinomas. Six patients with primary vulvar carcinomas and six patients with recurrent or metastatic vulvovaginal carcinomas underwent bone resection as part of their surgical therapy. Survival in the primary treatment group was 50%, with no local recurrences. Survival in the recurrent/metastatic disease group was 83%, with a follow-up time of 9 months to 15 years. One vulvar and one groin recurrence have occurred in the recurrent/metastatic group. Pubic bone resection added little to surgical morbidity and gave good functional results. Pubic bone resection, in combination with radical extirpative procedures, is an option for treatment of patients with locally extensive vulvovaginal carcinomas, particularly those with previous radiation therapy.

Entities:  

Mesh:

Year:  1989        PMID: 2726105     DOI: 10.1097/00006250-198906000-00023

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

1.  Hemipelvectomy: a changing perspective for a rare procedure.

Authors:  Christopher R Baliski; Norman S Schachar; J Gregory McKinnon; Gavin C Stuart; Walley J Temple
Journal:  Can J Surg       Date:  2004-04       Impact factor: 2.089

2.  HEMIPELVECTOMY: ERASTO GAERTNER HOSPITAL'S EXPERIENCES WITH 32 CASES IN 10 YEARS.

Authors:  Rosyane Rena de Freitas; André Luiz Soares Crivellaro; Glauco José Pauka Mello; Múrio Armani Neto; Geraldo de Freitas Filho; Letícia Viani da Silva
Journal:  Rev Bras Ortop       Date:  2015-11-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.